A share price of Biodexa Pharmaceuticals Plc ADR [BDRX] is currently trading at $1.69, up 14.97%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BDRX shares have gain 37.40% over the last week, with a monthly amount drifted -45.66%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biodexa Pharmaceuticals Plc ADR [NASDAQ: BDRX] stock has seen the most recent analyst activity on February 08, 2024, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $8.
Biodexa Pharmaceuticals Plc ADR experienced fluctuations in its stock price throughout the past year between $1.14 and $74.00. Biodexa Pharmaceuticals Plc ADR [NASDAQ: BDRX] shares were valued at $1.69 at the most recent close of the market.
Analyzing the BDRX fundamentals
Trailing Twelve Months sales for Biodexa Pharmaceuticals Plc ADR [NASDAQ:BDRX] were 0.10M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at -52.49% with Operating Profit Margin at -96.3%, Pretax Profit Margin comes in at -85.08%, and Net Profit Margin reading is -82.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.02 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5167 points at the first support level, and at 1.3433 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8867, and for the 2nd resistance point, it is at 2.0833.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Biodexa Pharmaceuticals Plc ADR [NASDAQ:BDRX] is 2.16. In addition, the Quick Ratio stands at 2.16 and the Cash Ratio stands at 1.45. Considering the valuation of this stock, the price to sales ratio is 9.80, the price to book ratio is 0.13.
